Innovative diagnostics for the Real World
Balancing doing well with doing good
DRW is dedicated to tackling some of the world’s most serious infectious diseases using breakthrough point of care (POC) diagnostics
The Real World’s needs are our drive for inventiveness
Decentralised molecular testing at the POC where patients are seen and where prompt clinical intervention can be initiated. Our mission is to develop high performance and simple to use diagnostic solutions.
Our activity
Read the latest news and activity from the DRW team.
NHS hospitals adopt the next-generation SAMBA to improve patient care
Leading NHS hospitals have adopted the SAMBA III rapid molecular diagnostics platform to transform the way patients with suspected respiratory infections are assessed and managed. “Using SAMBA III will give us greater flexibility meaning that our patients are cared for in the...
29 September 2025
DRW receives CTDA approval for SAMBA III respiratory molecular tests
Diagnostics for the Real World (DRW) is pleased to announce that its SAMBA III SARS-CoV-2 Test and SAMBA III SCoV-2/Flu/RSV Test have received approval under the UK Coronavirus Test Device Approvals (CTDA) process. Following a successful desktop review by the UK’s Medicines and Healthcare...
8 August 2025
The launch of SAMBA III: a new generation of rapid molecular diagnostics
Diagnostics for the Real World (DRW), a pioneer in rapid molecular diagnostics, today announces the launch of the SAMBA III Instrument System – its most advanced point-of-care molecular platform to date. Building on more than two decades of innovation, SAMBA III has...
20 April 2025